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Introduction: The axial symptoms of Parkinson disease (PD) include difficulties with
balance, posture, speech, swallowing, and locomotion with freezing of gait, as well as
axial rigidity. These axial symptoms impact negatively on quality of life for many patients,
yet remain poorly understood. Dopaminergic treatments typically have little effect on the
axial symptoms of PD, suggesting that disruptions in other neurotransmitter systems
beyond the dopamine systemmay underlie these symptoms. The purpose of the present
study was to examine the relationship between the axial symptoms of PD and GABA and
glutamate levels quantified with magnetic resonance spectroscopy.
Methods: The participant group included 20 patients with PD and 17 healthy control
participants. Water-scaled GABA and Glx (glutamate + glutamine) concentrations were
derived from GABA-edited MEGA-PRESS spectra acquired from the left basal ganglia
and prefrontal cortex, and additional water-scaled Glx concentrations were acquired from
standard PRESS spectra acquired from the pons. Spectra were analyzed with LCModel.
The axial symptoms of PD were evaluated from subscales of the Unified Parkinson’s
Disease rating scale (MDS-UPDRS).
Results: PD patients demonstrated significantly higher GABA levels in the basal
ganglia, which correlated with the degree of gait disturbance. Basal ganglia Glx levels
and prefrontal GABA and Glx levels did not differ significantly between patient and
control groups, but within the PD group prefrontal Glx levels correlated negatively with
difficulties turning in bed. Results from an exploratory subgroup analysis indicate that
the associations between GABA, Glx, and axial symptoms scores are typically more
prominent in akinetic-rigid patients than in tremor-dominant patients.
Conclusion: Alterations in GABAergic and glutamatergic neurotransmission may
contribute to some of the axial symptoms of PD.
Keywords: Parkinson disease, magnetic resonance spectroscopy, GABA, glutamate, basal ganglia, prefrontal
cortex, gait, axial symptoms
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INTRODUCTION
Parkinson disease (PD) is a progressive neurodegenerative
disorder thought to affect over 4 million patients worldwide
(1). The core motor symptoms of PD include akinesia, rigidity,
resting tremor, and postural and balance difficulties, but patients
can also suffer from a broad spectrum of non-motor symptoms
(2). While some of the motor symptoms can be improved by
dopaminergic (e.g., levodopa) therapy, the non-motor symptoms
and the “axial” motor symptoms, including difficulties with
gait, posture, speech, swallowing, and postural stability, typically
do not respond well to dopaminergic therapy (3). These axial
symptoms have a severe, long-lasting negative impact on quality
of life and have been identified as a top research priority by
patients, family members, and carers affected by PD, second only
to the overarching aim to find an effective cure (2).
The neural origin of the axial symptoms of PD is not
well-understood, and treatment options are limited. However,
converging evidence indicates that disruptions in other
neurotransmitter systems beyond the dopamine system are
present in PD and may underlie some of the non-motor and
axial symptoms (4–6).
Two of the other major neurotransmitter systems implicated
in basal ganglia regulation and in PD, namely the glutamate
and γ-amino butyric acid (GABA) systems, can be probed non-
invasively using magnetic resonance spectroscopy (MRS) (7).
Previous MRS studies in PD have reported increased GABA
in the pons, basal ganglia, and thalamus (8–10), decreased
cortical glutamate (11), and an increased GABA/glutamate
ratio in the substantia nigra (12). In other neurodegenerative
disorders, altered GABA and glutamate levels have been linked
to symptoms which are also present in PD, including cognitive
impairment (13, 14) and depression (15). In mice, altered GABA
and Glycine neurotransmission was observed to trigger the
cardinal features of rapid eye movement sleep behavior disorder
(RBD) (16), a premotor symptom of PD which may represent
a biomarker for overall disease severity (17). However, few
studies have examined altered GABA and glutamate levels in
relation to PD symptomatology, and currently the link between
alterations in the GABAergic and glutamatergic systems and
the axial symptoms of PD remains unclear. The purpose of the
present study was to examine the relationship between the axial
symptoms of PD, GABA, and glutamate levels in the basal ganglia
and prefrontal cortex, and glutamate levels in the pons. Based on
previous reports, we hypothesized that patients with PD would
show increased GABA levels in the basal ganglia and decreased
glutamate in the prefrontal cortex and pons, and that more
pronounced abnormalities in the GABA and glutamate levels
would correlate positively with the severity of the axial symptoms
of PD.
MATERIALS AND METHODS
Participants
The patient group consisted of 20 patients with PD (4
female, mean age 63 years, range 50–75) recruited from the
Neurology Department of the University Hospital of Zürich,
Switzerland (see Table 1 for demographics). All 20 patients
had bilateral impairment, and 9/20 patients were treated with
levodopa without dopamine agonists, while 11/20 patients were
treated with a combination of levodopa and dopamine agonists.
Patients were enrolled consecutively. Seventeen healthy control
participants (4 female, mean age 62 years, range 28–77) with no
history of neurological or psychiatric illness were also recruited.
All participants gave written and verbal informed consent to
participate in the study, which was approved by the cantonal
ethics committee of the Canton of Zürich, Switzerland.
MRI/MRS Acquisition and Analysis
Magnetic resonance imaging and spectroscopy data were
acquired with a 3T GE MR750 scanner (GE Healthcare,
Milwaukee,WI, USA), using an 8-channel receive-only head coil.
On the day of the scan, patients were scanned at a time when their
dopaminergic medication was wearing off, before their next dose
could be taken. The MRI protocol included a 3D T1-weighted
fast spoiled gradient echo (SPGR) scan (echo time (TE) = 3ms,
repetition time (TR) = 8ms, inversion time (TI)=600ms; voxel
resolution= 1× 1× 1 mm3, flip angle=8◦), used for localisation
of the MRS voxels and correction of the GABA and glutamate
levels for partial volume CSF contamination (18).
Single voxel PRESS spectra were acquired from a 3.4mL (15×
15× 15mm3) voxel in the pons, with TE= 35ms, TR= 3000ms,
128 spectral averages, and 16 unsuppressed water reference lines,
resulting in a total scan time of 7min, (see Figure 1 for an
illustration of the voxel positions and representative spectra).
Single-voxel GABA-edited spectra were acquired from a
30mL voxel centered on the left basal ganglia using the
MEGAPRESS method (19), with TE = 69ms, TR = 1800ms,
320 spectral averages (160 edit ON/OFF pairs), and an eight-step
phase cycle. MEGA-editing was achieved with 16-ms Gaussian
editing pulses applied at 1.9 and 7.5 ppm in alternate spectral
lines. For each metabolite spectrum, 16 unsuppressed water
reference lines were also acquired, resulting in a total acquisition
time of 10min. To achieve a consistent voxel position between
participants, voxels were prescribed on an axial plane where the
putamen was widest in the lateral (right-left) direction, such that
the anterior andmedial borders of the voxel were aligned with the
anterior and medial margins of the head of the caudate nucleus.
Additional GABA-edited MEGAPRESS spectra were collected
from a subset of n = 31 participants (n = 16 PD patients, n =
15 controls), using a 30mL voxel in in the left prefrontal cortex,
with TE = 69ms, TR = 1800ms, 320 spectral averages (160 edit
ON/OFF pairs), and an eight-step phase cycle. MEGA-editing
was achieved as described above for the basal ganglia. In order
to achieve a consistent voxel position between participants, the
voxel was localized according to a standard set of anatomical
measurements. (20).
Spectra were analyzed with LCModel version 6.31-H (21).
Edited MEGA-PRESS spectra were analyzed with a simulated
basis set including basis spectra for GABA, N-acetyl aspartate
(NAA), glutamate (Glu), Glutamine (Gln), glutathione, and N-
acetyl aspartyl glutamate (NAAG), using the control parameter
sptype=mega-press-3 to avoid mis-assignment of the spectral
baseline to the GABA peak (22). Since no attempt was
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TABLE 1 | Patient characteristics and MDS-UPDRS scores.
Patient Disease duration (years) PD Type Most affected side LED MDS-UPDRS
I II III IV
1 18 Akinetic rigid Right 1500 22 14 31 8
2 14 Tremor-dominant Right 1300 18 10 41 6
3 5 Tremor-dominant Right 600 8 15 13 6
4 6 Tremor-dominant Left 900 17 16 31 4
5 11 Akinetic rigid Left 1550 15 14 46 9
6 11 Akinetic rigid Right 1200 10 12 18 1
7 8 Tremor-dominant Left 800 8 7 25 6
8 8 Akinetic rigid Left 1500 11 10 27 10
9 16 Akinetic rigid Right 950 12 14 26 10
10 9 Tremor-dominant Left 800 13 17 21 8
11 5 Akinetic rigid Left 750 11 17 26 8
12 11 Akinetic rigid Left 1500 20 14 31 10
13 12 Akinetic rigid Right 1550 7 17 33 6
14 8 Tremor-dominant Left 450 12 14 20 10
15 3 Akinetic rigid Left 650 23 11 32 0
16 10 Akinetic rigid Right 850 14 10 21 9
17 12 Akinetic rigid Right 900 3 5 17 5
18 12 Tremor-dominant Left 1050 8 12 40 7
19 4 Tremor-dominant Left 1600 13 15 31 7
20 2 Tremor-dominant Left 775 15 5 29 6
made to quantify the co-edited macromolecule underlying the
GABA peak in the edited MEGAPRESS spectra, the GABA
concentrations should be considered to represent GABA+ rather
than pure GABA.
PRESS spectra from the pons were analyzed using a standard
GE basis set including basis spectra for Alanine, Aspartate,
Creatine, GABA, Glucose, Gln, Glu, glycerophosphorylcholine,
phosphorylcholine, lactate, myo-inositol, NAA, NAAG, Scyllo-
inositol, and Taurine. For all pontine PRESS spectra the default
LCModel baseline fit settings were used.
Metabolite concentrations were calculated in institutional
units (I.U.) after referencing each metabolite signal to the
unsuppressed water signal and correcting both the metabolite
and water signals for partial volume CSF contamination within
the voxel (18). Additional water and metabolite relaxation time
corrections were not performed. Since our hypotheses focused
on alterations in the GABA and glutamate systems, only the
GABA and Glx (Glu+Gln) levels from the basal ganglia and
prefrontal cortex, and the Glx levels from the pons were
entered into the statistical analysis (see below for statistical
methods).
Symptom Evaluation
Axial symptoms were evaluated from subscales of the Unified
Parkinson’s Disease rating scale (MDS-UPDRS) (23) including
speech/dysarthria (2.1), swallowing (2.3), turning in bed
(2.9), arising from a chair (3.9), freezing of gait (2.13,
3.11), gait (3.10), postural stability (3.12), and posture (3.13).
Since several symptom scores pertain to gait disturbance,
a summary score for the gait symptoms was derived by
summing together the individual scores for items 2.13, 3.10,
and 3.11, and an overall summary score of the axial symptoms
was also derived by adding together the symptom scores
from each of the axial subscales. The UPDRS scores were
derived while the patients were in the ON medication
state.
Statistical Analysis
GABA and Glx concentrations and symptom scores were tested
for normality with a Shapiro-Wilk test. Group comparisons
(PD vs. control) were assessed with a two-sided t-test for
normally-distributed variables and a Mann-Whitney test for
non-normally distributed variables. A non-parametric bivariate
correlation (Spearman’s rho) was used to investigate the
association between GABA and Glx levels and axial symptom
scores from the MDS-UPDRS. In the event of a significant
group difference or correlation emerging for Glx, post-hoc tests
were performed to ascertain if this difference or association
was driven by Glu or Gln. Since the patient group included
both tremor-dominant and akinetic-rigid PD patients who
are known to demonstrate differences in the progression
of axial motor symptoms, (24–26) the relationship between
GABA and Glx levels and the overall axial summary score
was evaluated in the tremor-dominant and akinetic-rigid
subgroups separately, after dichotomising patients according
to their motor signs at disease onset (27). In the event of
a significant association between the axial summary score
and neurotransmitter levels emerging in one or both of the
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FIGURE 1 | Voxel positions and representative spectra from one PD patient. (A) voxel positions from the basal ganglia, prefrontal cortex, and pons voxels,
respectively. (B) GABA-edited MEGAPRESS spectra from the basal ganglia (top) and prefrontal cortex (middle). The spectral data are plotted in black and the
LCModel fit for each spectrum is overlaid in red. (C) PRESS spectrum from the pons, with the LCModel fit overlaid in red. For all spectra, the residuals of the fit are
plotted above each spectrum.
subgroups, additional post-hoc correlations with the individual
symptom scores were performed in the relevant subgroup(s)
in order to ascertain which symptoms were likely to underly
the observed association with neurotransmitter levels. In order
to investigate the influence of medication on the association
between neurotransmitter levels and symptom scores, additional
post-hoc correlations were also performed for all significant
associations between GABA, Glx, and symptom scores after
controlling for the levodopa equivalent dose. All statistical
analyses were performed with SPSS version 22, with a two-tailed
significance threshold of p < 0.05. No correction was made for
multiple comparisons.
RESULTS
Representative spectra from the pons, basal ganglia, and
prefrontal cortex in one PD participant are shown in Figure 1,
together with images depicting the voxel positions.
GABA-edited MEGAPRESS data was not collected from one
patient with a lesion in the basal ganglia, and the basal ganglia
Glx levels were excluded for one patient in whom an artifact
was visible over the Glx doublet in the MEGA-PRESS subtraction
spectrum.
Glx levels in the pons and GABA levels in the basal ganglia
followed a normal distribution, but GABA and Glx levels in the
Frontiers in Neurology | www.frontiersin.org 4 September 2018 | Volume 9 | Article 806
O’Gorman Tuura et al. GABA, Glutamate and Axial Parkinson’s Symptoms
TABLE 2 | Demographic data and neurotransmitter levels for the PD and control
groups.
PD Controls PD vs. Control
Age (Median ± IQR) 62.9 ± 11.5 66.2 ± 12.4 p = 0.563
(Mean ± SD) 63.6 ± 6.8 62.5 ± 12.8
Gender 16M, 4 F 13M, 4 F p = 0.798
Left Basal Ganglia GABA§ 4.61 ± 0.57 3.93 ± 0.75 p = 0.005*
Left Basal Ganglia Glx 8.27 ± 3.5 6.66 ± 2.0 p = 0.069
Left Prefrontal GABA 3.48 ± 0.90 2.96 ± 0.96 p = 0.114
Left Prefrontal Glx 8.19 ± 0.98 7.98 ± 0.84 p = 0.114
Pons Glx§ 13.6 ± 4.02 14.2 ± 3.16 p = 0.58
§ Indicates a normally distributed variable, described by Mean ± SD.
Data are summarized as median ± inter-quartile range and tested with a Mann-Whitney
U test unless indicated otherwise. [MRS levels are given in institutional units (I.U.)].
prefrontal cortex and Glx levels in the basal ganglia were not
normally distributed (p < 0.05, Shapiro–Wilk test). The axial
symptom scores and the corresponding summary score were also
not normally distributed (p < 0.05, Shapiro–Wilk test).
PD and control groups did not differ in terms of age or
gender (p > 0.5, Mann–Whitney test, see Table 2). PD patients
demonstrated increased GABA in the basal ganglia (t = 2.874,
p = 0.007, 2-tailed t-test). After removal of one outlier in the PD
group with a GABA level 6 standard deviations away from the
mean, GABA levels in the basal ganglia remained significantly
higher in the PD group (t = 3.009, p = 0.005, 2-tailed t-test).
The corresponding Glx data for this outlier was also removed
from further statistical analyses. No significant differences were
observed between GABA and Glx levels in the prefrontal cortex
or Glx levels in the basal ganglia and pons between the PD and
control groups.
Significant associations between GABA and Glx
concentrations and axial symptom scores are plotted in Figure 2.
GABA levels in the left basal ganglia correlated positively with
the gait summary score (Spearman’s rho = 0.491, p = 0.038),
as well as the individual gait (MDS 3.10) subscore (Spearman’s
rho = 0.495, p = 0.037) of the motor part of the MDS-UPDRS.
Both correlations were present at trend level in the subgroup of
akinetic-rigid patients (Gait summary score: Spearman’s rho =
0.580, p= 0.079, MDS 3.10: Spearman’s rho = 0.604, p= 0.064),
but not in the tremor-dominant subgroup. For the summary
score incorporating all the axial symptoms from the UPDRS,
basal ganglia GABA levels showed a trend-level association in
the full patient group (Spearman’s rho = 0.441, p = 0.067),
which was significant in the subgroup of akinetic rigid patients
(Spearman’s rho = 0.671, p = 0.034), but not in the subgroup of
tremor-dominant patients (Spearman’s rho = 0.345, p = 0.403).
In the subgroup of akinetic-rigid patients, basal ganglia GABA
levels were significantly correlated with difficulties arising from
a chair (MDS 3.9, Spearman’s rho = 0.838, p = 0.002 and with
posture (MDS 3.13, Spearman’s rho= 0.838, p= 0.002).
No significant correlations were observed between basal
ganglia or pontine Glx levels and the axial symptom scores,
but prefrontal Glx levels were negatively correlated with the
turning in bed (MDS 2.9) subscore, both in the full patient group
(Spearman’s rho= −0.546, p = 0.029), and in the subgroup of
akinetic-rigid patients (Spearman’s rho = −0.686, p = 0.041).
Prefrontal GABA levels were negatively correlated with the
postural stability score (MDS 3.12, Spearman’s rho = - 0.842, p
= 0.004), in the akinetic-rigid subgroup only.
The correlations between basal ganglia GABA and the
gait subscore and summary score became non-significant
after controlling for the levodopa equivalent dose (Spearman’s
rho=0.324/0.341, p = 0.224/0.196 for the gait summary score
and subscore, respectively), as did the correlation between
basal ganglia GABA levels and the axial symptom summary
score in the akinetic-rigid subgroup (Spearman’s rho =0.403,
p = 0.322) However, correlations between basal ganglia GABA
levels and difficulties arising from a chair (MDS 3.9) remained
significant in the akinetic-rigid subgroup after controlling
for levodopa equivalent dose (Spearman’s rho = 0.845, p =
0.008), as did the correlation between basal ganglia GABA and
problems with posture (MDS 3.13, Spearman’s rho = 0.845,
p = 0.008). The correlation between prefrontal Glx and turning
in bed diminished to trend level after controlling for levodopa
equivalent dose (Spearman’s rho = −0.491, p = 0.074), but
the correlation between prefrontal GABA and difficulties with
postural stability (MDS 3.12) in the akinetic-rigid subgroup
remained significant after controlling for the levodopa equivalent
dose (Spearman’s rho= −0.76, p= 0.047).
DISCUSSION
Gait and locomotion, turning in bed, arising from a chair, and
postural stability all depend on efficient sensorimotor integration
(28, 29), which is affected in PD (30–32). The basal ganglia
act as an important hub for sensorimotor integration (33, 34)
and descending basal ganglia projections to the midbrain have
been reported to play an important role in gait and postural
control (35, 36). One of the ways in which the basal ganglia are
thought to influence sensorimotor integration is by gating or
controlling the access of sensory information to motor neurons,
via a balance of neurotransmitter activity (30, 37, 38). In PD, the
motor systems can become hypo-excitable following an increased
inhibition of sensory inputs to the basal ganglia, leading to
a diminished motor response to certain sensory stimuli (30).
This diminished responsiveness to sensory stimuli is thought to
underly the observed difficulties experienced by PD patients in
regulating the amplitude of movements in the absence of external
visual or auditory cues, when they are dependent on sensory
feedback for accurate motor control, (31, 32, 38) and may also
contribute to the axial symptoms.
In the present study, the observed link between increased
GABA levels in the left basal ganglia in PD patients and the
degree of gait disturbance (Figure 2) may be associated with an
over-inhibition of the processing of sensory inputs necessary for
maintaining posture and initiating locomotion. This observation
is consistent with the reported role of GABAergic outputs from
the basal ganglia in the control of posture and locomotion (35, 39,
40). However, since locomotion can be initiated by stimulation
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FIGURE 2 | Basal ganglia GABA, prefrontal GABA and prefrontal Glx appear to be associated with axial symptom scores including gait and postural difficulties
assessed with the MDS-UPDRS. (A) left basal ganglia GABA levels were significantly associated with higher axial symptom summary scores in akinetic-rigid (AKR)
patients (p = 0.034), but not in tremor-dominant (TD) patients (p = 0.403), while the full patient group showed a trend-level association between basal ganglia GABA
and axial summary scores (p = 0.067). (B) Elevated GABA levels were also associated higher gait summary scores (p = 0.038, full group). In the AKR subgroup,
increased GABA levels were significantly positively associated with difficulties arising from a chair (C, p = 0.002) and difficulties with posture (D, p = 0.002). Left
prefrontal GABA levels were negatively associated with postural stability in the AKR subgroup (p = 0.004, E), while left prefrontal Glx levels were negatively associated
difficulties turning in bed, both in the full group (p = 0.029, F), and in the AKR subgroup (p = 0.041, F).
of the midbrain locomotor region, (36) one would expect
corresponding neurotransmitter abnormalities to be observed in
the pons, related to problems with gait. In the present study,
we were not able to measure GABA in the pons due to the
large voxel size required for GABA measurement with MEGA-
PRESS, but we did not observe any apparent relationship between
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the pontine Glx concentrations (from standard PRESS) and
problems with gait. However, since the PRESS voxel volume
(3.4mL) is large in comparison to the size of the midbrain
locomotor region or the peduculopontine nucleus of the pons,
two of the pontine regions implicated in gait control and muscle
tone regulation, the lack of an apparent relationship between
pontine Glx and posture or gait symptoms may be due to a lack
of regional specificity of the pontine MRS measurement. Future
studies at higher field strengths (e.g., 7T), where smaller voxel
volumes can be used and where GABA can be quantified without
the need for spectral editing, may be able to extend the present
findings to clarify the link between gait difficulties and pontine
neurotransmitter levels.
In the subgroup analysis, the observed link between basal
ganglia GABA levels and the gait and axial summary scores
seemed to be mostly driven by GABA and symptom changes in
the akinetic-rigid subgroup of patients rather than the tremor-
dominant patients. Longitudinal studies have shown that the
akinetic-rigid subtype of PD presents a risk factor for greater
progression of the motor symptoms, including freezing of gait
and other axial symptoms. (24–26) Akinetic-rigid PD patients
have also been shown to demonstrate differences in structural
and functional connectivity in comparison to tremor-dominant
patients, (41–43) and differences in iron deposition between the
subtypes indicates that different pathological mechanisms may
underly the observed differences in symptom progression (44).
In light of the small group sizes, the subgroup analysis in the
present study should be considered exploratory, and we hope
these results can be replicated in a larger sample. Given the
evidence for differences in brain structure and function as well
as symptom progression in different subtypes of PD, it would
be interesting to examine differences in the metabolite profile,
including neurotransmitter changes, between akinetic-rigid and
tremor-dominant PD patients in more detail in a larger cohort.
While basal ganglia GABA levels appeared to be related to
gait difficulties, prefrontal Glx levels correlated negatively with
difficulties turning in bed (Figure 2), and prefrontal GABA levels
correlated negatively with postural stability, in the akinetic-rigid
subgroup. The negative correlation between prefrontal Glx and
symptom scores would be consistent with previous reports of
decreased cortical Glx in PD, (11) under the assumption that
patients more severely affected by axial symptoms like turning
in bed would have lower prefrontal Glx levels. However, since in
the present study no significant differences in prefrontal Glx were
observed at the group level, the apparent correlation between
frontal Glx and symptom scores seen in the present study cannot
be interpreted in the context of abnormal Glx levels in the
patient group. The link between prefrontal GABA and posture is
also consistent with the putative role of prefrontal and parietal
cortical regions in maintaining postural equilibrium, (45) but
should also be interpreted with caution in light of the lack of
a significant difference in prefrontal GABA between the patient
and control groups. It is possible that these associations with
individual symptom scores may be affected by outliers, given the
small group sizes and the limited distribution of symptoms in
some domains. These results should therefore be considered with
caution until they can be replicated in a larger sample.
Since the symptom scores were assessed while patients were
in the ON medication state, while the MRS was performed just
before the next dose was due and thus rather in an OFF state,
medication effects could potentially confound the comparison
between GABA and Glx levels and the axial symptom scores.
While most of the axial symptoms do not typically respond well
to levodopa, dopamine replacement therapy has been reported
to reduce freezing of gait in patients with PD, (46) and in the
present sample the levodopa equivalent dose showed a trend-
level association with basal ganglia GABA (p = 0.09, Spearman’s
rho). The effect of levodopa on freezing of gait may explain
why the correlations between basal ganglia GABA levels and
the gait and axial symptom summary scores diminished in
significance after controlling for the levodopa equivalent dose,
particularly in akinetic-rigid patients. In contrast, the association
between neurotransmitter levels and other symptom scores such
as rising from a chair, turning in bed, posture, and postural
stability, seemed relatively independent of levodopa effects, but
in addition to levodopa 11 patients were additionally medicated
with dopamine agonists. Previous studies in children with
attention deficit hyperactivity disorder (ADHD) have reported
that treatment with dopamine agonists like methylphenidate can
reduce striatal Glx levels (47), although methylphenidate did not
appear to influence frontal Glx levels, (47) and another study of
medication-naïve andmedicated adults with ADHD failed to find
differences in Glx related to medication status (48). However,
since treatment with dopamine agonists or other medications
may introduce additional variability into the Glx and GABA
signals measured MRS, it would be instructive to clarify the
effects of dopaminergic and other medications on the GABA and
Glx levels in a future study, where the cohort of PD patients is
sufficiently large to enable separation into subgroups according
to medication status.
CONCLUSION
MRS offers a unique opportunity to study the complex interplay
between excitatory and inhibitory neurotransmitter activity both
within and outside the motor network. The present pilot
study provides evidence of a link between alterations in GABA
and glutamate levels and the axial symptoms of Parkinson’s
disease, lending important insight into the neural origin of these
symptoms, and opening up potential avenues for treatment.
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